Abstract
The effects of the MAO-B inhibitors, L-deprenyl and MDL-72974 on MDMA-induced serotonergic neurotoxicity in rats were examined. MDMA alone produced a significant decrease in the number of 5-HT uptake sites, measured as a decrease in theB max for binding of [3H]paroxetine, and in 5-HT and 5-HIAA levels in the striatum.l-Deprenyl and MDL-72974 attenuated this MDMA-induced decrease in serotonergic markers. The data suggest a key role for MAO-B in the expression of the neurotoxicity produced by MDMA in the striatum.
This is a preview of subscription content, log in via an institution to check access.
References
Battaglia GS, Yeh SY, O'Hearn E, Molliver MC, Kuhar MJ, DeSouza EB (1987) 3,4-methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]-paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 242:911–916
Berger UB, Grzanna R, Molliver ME (1992) The neurotoxic effects ofp-chloroamphetamine in rat brain are blocked by prior depletion of serotonin. Brain Res 58:177–185
Faraj BA, Olkowski ZL, Jackson RT (1994) Active [3H]-dopamine uptake by human lymphocytes: correlates with serotonin transporter activity. Pharmacology 48:320–327
Marcusson JO, Bergstrom M, Eriksson K, Ross SB (1988) Characterization of [3H]paroxetine binding in the rat brain. J Neurochem 50:1783–1790
McKenna DJ, Peroutka SJ (1990) Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”). J Neurochem 54:14–19
Nash JF (1990) Ketanserin pretreatment attenuates MDMA-induced DA release in the striatum as measured by in vivo microdialysis. Life Sci 47:2401–2408
Nash JF, Nichols DE (1991) Microdialysis studies of 3,4-methyl-enedioxymethamphetamine and structurally related analogues. Eur J Pharmacol 200:53–58
Schmidt CJ, Taylor VL (1990) Reversal of the effects of 3,4-methylenedioxymethamphetamine by 5-HT uptake inhibitors. Eur J Pharmacol 181:133–136
Schmidt CJ, Black CK, Taylor VL (1991) L-Dopa potentiation of sertonergic deficits due to single adminstration of 3,4-methyenedioxymethamphetamine,p-chloroamphetamine or methamphetamine to rats. Eur J Pharmacol 203:41–49
Sprague JE, Huang X, Kanthasamy A, Nichols DE (1994) Attenuation of 3,4-methylenedioxymethamphetamine (MDMA) induced neurotoxicity with the serotonin precursors tryptophan and 5-hydroxytryptophan. Life Aci 55[15]:1193–1198
Stone DM, Johnson, M, Hanson GR, Giff JW (1988) Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther 247:79–87
Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW (1985) Distinct monamine oxidase A and B populations in primate brain. Science 230:181–183
Zreika M, Fozard J, McDonald I, Dudley M, Palfreyman M (1987) A potent and selective inhibitor of MAOB with potential for use in Parkinson's disease. European Winter Conf. Brain Res, Val Thoreus, France, March
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sprague, J.E., Nichols, D.E. Inhibition of MAO-B protects against MDMA-induced neurotoxicity in the striatum. Psychopharmacology 118, 357–359 (1995). https://doi.org/10.1007/BF02245967
Received:
Revised:
Issue date:
DOI: https://doi.org/10.1007/BF02245967
